Elanco Animal Health (ELAN) will release its results on Monday
Elanco Animal Health (NYSE:ELAN – Get Rating) will release quarterly results before market open on Monday, May 9. Analysts expect Elanco Animal Health to post earnings of $0.35 per share for the quarter. Those interested in participating in the company’s earnings conference call can do so using this link.
Elanco Animal Health (NYSE:ELAN – Get Rating) last reported quarterly results on Thursday, February 24. The company reported earnings per share of $0.21 for the quarter, beating Thomson Reuters consensus estimate of $0.17 by $0.04. Elanco Animal Health had a positive return on equity of 6.59% and a negative net margin of 9.91%. The company posted revenue of $1.11 billion in the quarter, versus analyst estimates of $1.10 billion. In the same quarter of the previous year, the company achieved EPS of $0.12. Elanco Animal Health revenue for the quarter decreased 2.3% compared to the same quarter last year. On average, analysts expect Elanco Animal Health to post EPS of $1 for the current fiscal year and EPS of $1 for the next fiscal year.
Shares of Elanco Animal Health opened at $25.31 on Monday. The company has a quick ratio of 1.16, a current ratio of 1.99 and a debt ratio of 0.80. Elanco Animal Health has a 12-month minimum of $24.15 and a 12-month maximum of $37.49. The company has a 50-day moving average price of $26.57 and a 200-day moving average price of $28.18. The company has a market capitalization of $11.98 billion, a PE ratio of -26.36, a P/E/G ratio of 1.09 and a beta of 0.78.
In other Elanco Animal Health news, Director R David Hoover acquired 5,000 shares of the company in a transaction that took place on Tuesday, March 1. The shares were purchased at an average cost of $28.66 per share, for a total transaction of $143,300.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, accessible via this hyperlink. Company insiders hold 6.11% of the company’s shares.
A number of institutional investors and hedge funds have recently increased or reduced their stake in ELAN. Guggenheim Capital LLC increased its stake in Elanco Animal Health by 71.6% in the fourth quarter. Guggenheim Capital LLC now owns 18,787 shares of the company valued at $533,000 after acquiring an additional 7,839 shares in the last quarter. CIBC World Markets Inc. acquired a new position in Elanco Animal Health during the fourth quarter worth $376,000. MML Investors Services LLC increased its stake in Elanco Animal Health by 6.7% during the fourth quarter. MML Investors Services LLC now owns 15,449 shares of the company worth $438,000 after purchasing an additional 974 shares in the last quarter. Mackenzie Financial Corp increased its stake in Elanco Animal Health by 18.8% during the fourth quarter. Mackenzie Financial Corp now owns 39,328 shares of the company worth $1,116,000 after buying 6,225 more shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC acquired a new position in Elanco Animal Health during the fourth quarter at a value of $1,167,000. Hedge funds and other institutional investors hold 97.90% of the company’s shares.
Several research companies have commented on ELAN. Zacks Investment Research upgraded Elanco Animal Health from a “sell” rating to a “hold” rating in a Monday, Feb. 28 research note. Barclays raised its price target on Elanco Animal Health from $30.00 to $32.00 and gave the stock an “equal weight” rating in a Monday, February 28 research note. Four investment analysts gave the stock a hold rating and six gave the company a buy rating. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $38.43.
Company Profile Elanco Animal Health (Get a rating)
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures and markets pet and farm animal products. It offers disease prevention products for companion animals, such as parasiticide products and vaccines that protect animals against worms, fleas and ticks under the brand names Seresto, Advantage, Advantix and Advocate; companion animal health therapies for pain, osteoarthritis, ear infections, cardiovascular and dermatological indications in dogs and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides and other products for poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides and other products used in ruminant and swine production under the Rumensin and Baytril brands.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Elanco Animal Health right now?
Before you consider Elanco Animal Health, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Elanco Animal Health didn’t make the list.
While Elanco Animal Health currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here